• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Biocon receives 12 USFDA observations for Malaysia unit

biospectrumasiaJuly 10, 2019

Tag:

Indian biopharmaceutical company Biocon has announced that its Sdn Bhd’s Insulin Glargine Drug Substance, Drug Product and Device assembly facilities in Malaysia underwent a pre-approval inspection by the U.S. FDA between June 24 and July 5, 2019. The inspection across these 3 units concluded with 12 observations issued on the Form 483.

The company will respond to the FDA with a Corrective and Preventive Action Plan and are confident of addressing these observations expeditiously. Biocon does not expect any change to its commercialization plans for Insulin glargine in the U.S. Biocon remains committed to global standards of Quality and Compliance.

Previous:NUS opens new centre for oral health

Next:DTC genetic testing market size to exceed $2.5bn by 2025

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Biocon receives 12 USFDA observations for Malaysia unit | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Marigold P.E.

Marigold P.E.
Bis(diphenylphosphino)methane

Bis(diphenylphosphino)methane
Tazobactam

Tazobactam
N-[[(5S)-3-[3-fluoro-4-(4-oxido -4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]acetamide

N-[[(5S)-3-[3-fluoro-4-(4-oxido -4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]acetamide
PEG300/400/600/660

PEG300/400/600/660
H-γ-Glu-Abu-Gly-OH

H-γ-Glu-Abu-Gly-OH
Anastrozole EPImpurity C

Anastrozole EPImpurity C
Beta Ecdysterone

Beta Ecdysterone
L-Cysteine HCl Anhydrous

L-Cysteine HCl Anhydrous
20%, 40%, 50%, 60%, 80%, 90% isoflavones Soybean Extract Soy Isoflavones

20%, 40%, 50%, 60%, 80%, 90% isoflavones Soybean Extract Soy Isoflavones

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service